Abstract
The in vivo dose-response potential of recombinant human granulocyte colony-stimulating factor (rG-CSF) in facilitating reconstitution of granulopoiesis was evaluated in an 11-year-old girl who received autotransplantation of peripheral blood stem cells (PBSC) after marrow-ablative therapy for relapsing acute lymphoblastic leukemia. The recovery of hematopoiesis was slow when a small number of progenitors were collected and reinfused into the patient, but administration of rG-CSF led to significant dose-dependent increase in peripheral blood granulocytes.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Blood Transfusion, Autologous*
-
Child
-
Colony-Stimulating Factors / therapeutic use*
-
Combined Modality Therapy
-
Dose-Response Relationship, Drug
-
Female
-
Granulocyte Colony-Stimulating Factor
-
Granulocytes / drug effects*
-
Hematopoiesis / drug effects
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Leukocyte Count / drug effects
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Recombinant Proteins / therapeutic use
Substances
-
Colony-Stimulating Factors
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor